![](https://cdn.sanity.io/images/0vv8moc6/genetherapy/f42cf5e88e95cf3ad2098e209fd9cf1ea8f9c5d8-1920x1080.png?fit=crop&auto=format)
SPEARHEAD-1 Supports Potential TCR-T Approval for Synovial Sarcoma
Afamitresgene autoleucel (afami-cel; Adaptimmune Therapeutics) is an investigational MAGE-A4–targeted autologous engineered T-cell receptor (TCR) SPEAR T-cell therapy intended to treat synovial sarcoma (SS) in HLA*02-positive patients. The therapy is …